lyophilized powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-25 and is reviewed periodically as new material appears.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Topoisomerases are enzymes with both nuclease and ligase activity. These proteins change the amount of supercoiling in DNA. Some of these enzymes work by cutting the DNA helix and allowing one section to rotate, thereby reducing its level of supercoiling; the enzyme then seals the DNA break. Other types of these enzymes are capable of cutting one DNA helix and then passing a second strand of DNA through this break, before rejoining the helix. Topoisomerases are required for many processes involving DNA, such as DNA replication and transcription. Helicases are proteins that are a type of molecular motor. They use the chemical energy in nucleoside triphosphates, predominantly adenosine triphosphate (ATP), to break hydrogen bonds between bases and unwind the DNA double helix into single strands. These enzymes are essential for most processes where enzymes need to access the DNA bases.
As part of the Synthetic Yeast 2.0 project, various research groups around the world have participated in a project to synthesise synthetic yeast genomes, and through this process, optimise the genome of the model organism Saccharomyces cerevisiae. The Yeast 2.0 project applied various DNA assembly methods that have been discussed above, and in March 2014, Jef Boeke of the Langone Medical Centre at New York University, revealed that his team had synthesized chromosome III of S. cerevisiae. The procedure involved replacing the genes in the original chromosome with synthetic versions and the finished synthetic chromosome was then integrated into a yeast cell. It required designing and creating 273,871 base pairs of DNA – fewer than the 316,667 pairs in the original chromosome. In March 2017, the synthesis of 6 of the 16 chromosomes had been completed, with synthesis of the others still ongoing.
Flagella in eukaryotes are supported by microtubules in a characteristic arrangement, with nine fused pairs surrounding two central singlets. These arise from a basal body. In some flagellates, flagella direct food into a cytostome or mouth, where food is ingested. Flagella role in classifying eukaryotes. Among protoctists and microscopic animals, a flagellate is an organism with one or more flagella. Some cells in other animals may be flagellate, for instance the spermatozoa of most animal phyla. Flowering plants do not produce flagellate cells, but ferns, mosses, green algae, and some gymnosperms and closely related plants do so. Likewise, most fungi do not produce cells with flagellae, but the primitive fungal chytrids do. Many protists take the form of single-celled flagellates.
24. Adv Gerontol. 2008;21(1):68-73. [Biological activity of regulatory peptides in model experiments in vitro]. [Article in Russian] Kozina LS, Arutiunian AV, Stvolinskiĭ SL, Khavinson VKh. Biological effects of short regulatory peptides, pinealon, vesugen, vilon and epitalon were studied in model experiments in vitro. These peptides were found not to demonstrate direct antioxidant activity but be able to restrict lipid peroxidation of human lipoproteins by modification of their structure. The short peptides increase stability of red blood cell membranes toward osmotic hemolysis. They also elevate the stationary level of intracellular reactive oxygen species and at the same time decrease (all excepting epitalon) percent of dead cells in neuronal population. The suggestion was made that under in vivo conditions, short peptides may participate in apoptosis/necrosis regulation.
About 75% of the fluorine-18 activity remains in tissues and is eliminated with a half-life of 110 minutes, presumably by decaying in place to O-18 to form [18O]O-glucose-6-phosphate, which is non-radioactive (this molecule can soon be metabolized to carbon dioxide and water, after nuclear transmutation of the fluorine to oxygen ceases to prevent metabolism). Another fraction of [18F]FDG, representing about 20% of the total fluorine-18 activity of an injection, is excreted renally by two hours after a dose of [18F]FDG, with a rapid half-life of about 16 minutes (this portion makes the renal-collecting system and bladder prominent in a normal PET scan). This short biological half-life indicates that this 20% portion of the total fluorine-18 tracer activity is eliminated renally much more quickly than the isotope itself can decay. Unlike normal glucose, FDG is not fully reabsorbed by the kidney. Because of this rapidly excreted urine 18F, the urine of a patient undergoing a PET scan may therefore be especially radioactive for several hours after administration of the isotope. All radioactivity of [18F]FDG, both the 20% which is rapidly excreted in the first several hours of urine which is made after the exam, and the 80% which remains in the patient, decays with a half-life of 110 minutes (just under two hours).
Sources: en.wikipedia.org
== Pharmacology == Teneligliptin has unique J-shaped or anchor locked domain structure because of which it has a potent inhibition of DPP 4 enzyme. Teneligliptin significantly controls glycemic parameters with safety. No dose adjustment is required in renally impaired patients.
Limulus polyphemus, Atlantic horseshoe crab (2014) Carcinoscorpius rotundicauda, mangrove horseshoe crab (2021) Tachypleus gigas, coastal horseshoe crab (2020) Tachypleus tridentatus, tri-spine horseshoe crab (2021) Order Ixodida:
==== Poor positioning ==== Poor positioning or poor latching of infants refers to the infant's inappropriate fastening onto the mother's nipple in breastfeeding. It is the most common cause of early and persistent nipple soreness. During breastfeeding, if the infant's mouth is not in the same plane as the mother's nipple and the infant's ears, shoulders and hips are not in parallel, the child cannot grasp enough portion of the nipple and areola into the mouth nor receive enough milk. The infant will sip more vigorously and thus reduce blood flow (ischemia) at the nipple which leads to vasospasm and blanched nipples.
Compared with other modes of transport such as aviation and rail, however, driverless technologies for road transport have lagged behind due to road environments being more complex than separated spaces for rail and air transport.
Sources: en.wikipedia.org
==== GSK–Novartis consumer healthcare buy-out ==== In March 2018, GSK announced that it has reached an agreement with Novartis to acquire Novartis's 36.5% stake in their Consumer Healthcare Joint Venture for US$13 billion (£9.2 billion).
The mechanism of action of bottromycin was confirmed nearly 20 years following the discovery of bottromycin. Bottromycin functions as an antibiotic through inhibition of protein synthesis. It blocks aminoacyl tRNA binding to the ribosome by binding to the A site of the 50s subunit. This results in release of aminoacyl tRNA from the ribosome and premature termination of protein synthesis. A comparison of other antibiotics known to bind to the A site of the ribosome, including micrococcin, tetracycline, streptomycin, and chloramphenicol, suggested that only bottromycin and chloramphenicol caused release of aminoacyl tRNA from the ribosome. Of those antibiotics, only micrococcin is also a macrocyclic peptide.
== Later life and legacy == Ramachandran was devastated by the death of his wife Rajalakshmi in 1998 and his health gradually deteriorated. During the last few years of his life, he suffered a stroke and was affected by Parkinson's disease. Ramachandran died on 7 April 2001, aged 78, in Chennai. Each year, the Council of Scientific and Industrial Research (CSIR) awards the "G N Ramachandran Gold Medal for Excellence in Biological Sciences & Technology" in his memory for work in Biological Sciences & Technology.
There has been uncertainty about which biological target interactions mediate the psychoactive and other effects of ibogaine. Rodent drug discrimination studies with ibogaine have been employed to help elucidate these interactions. Ibogaine partially substitutes for the serotonergic psychedelics LSD and DOM and this can be blocked by the serotonin 5-HT2 receptor antagonist pizotifen. Similarly, LSD and DOM partially substitute for ibogaine and this can be blocked by the serotonin 5-HT2A receptor antagonist pirenperone. The serotonin releasing agent and potent serotonin 5-HT2 receptor agonist fenfluramine also partially substitutes for ibogaine. The preferential serotonin 5-HT2C receptor agonists MK-212 and mCPP partially substitute for ibogaine as well and this can be blocked by the serotonin 5-HT2 receptor antagonist metergoline. The preceding findings suggest that serotonin 5-HT2A and 5-HT2C receptor activation are involved in the subjective effects of ibogaine. Conversely, the serotonin 5-HT1A and 5-HT3 receptors do not appear to be involved. Although serotonin 5-HT2A receptor signaling appears to be involved in the effects of ibogaine, neither ibogaine nor its major active metabolite noribogaine appears to act as a direct serotonin 5-HT2A receptor agonist. In addition, in contrast to the findings in drug discrimination studies, ibogaine fails to produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.
== History == Dimercaptosuccinic acid was first synthesized by V. L. Nirenburg in the Urals Polytechnic Institute, commissioned by one of the electrical enterprises of Sverdlovsk, Russia, which consumed many tons of mercury and was looking for a medicine to prevent poisoning of personnel. In 1957, Chinese scientists found that dimercaptosuccinic acid can effectively treat antimony poisoning due to overdose of tartar emetic. Pronounced protective effect in animal poisoning with arsenic and mercury was first shown by I. E. Okonishnikova in 1962. In 1984, the now-defunct Bock Pharmaceutical Company requested the FDA grant approval for orphan drug status under the brand name Chemet and the FDA approved of this in 1991. It provided exclusivity until 1998 which was conveyed to the successor Sanofi in 1996.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.